ATC group | Use in treated participants with T2D | Use in treated participants without T2D | Comment | |||
---|---|---|---|---|---|---|
N = 760 (%) single or in combination with other preparations | as spreparation/ATC group | N = 3852 (%) single or in combination with other preparations | as single preparation/ATC group | |||
C02 | Anti-hypertensives | 9.47 | 2.11 | 8.00 | 2.78 | |
C03 | Diuretics | 29.47 | 2.50 | 17.29* | 2.52 | not ideal as first line treatment since they can worsen glucose and lipid levels |
C04 | Peripheral vasodilators | 4.21 | 0.13 | 2.65* | 0.31 | |
C07 | Beta blocking agents | 44.74 | 8.82 | 52.23* | 23.81* | best used as second- or third-line treatments in T2D, more efficacious in younger patients (55–60 years), not for asthma patients, because of bronchoconstrictive effects, promote weight gain, may mask hypoglycaemia |
C08 | Calcium channel blockers | 33.68 | 5.79 | 27.13* | 7.84* | not recommended as first-line and single treatment |
C09 | Agents acting on the renin-angiotensin system | 68.95 | 20.53 | 51.43* | 18.98 | recommended as first-line treatment, reduce the risk for renal end points |